Rezafungin

Summary

Rezafungin (CHEMBL3989945) is an approved small molecule; indicated across 2 conditions including fungal infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 7
• Chemistry: 1226.4 Da · C63H85N8O17+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3989945
Name	Rezafungin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	78318119
ChEBI	CHEBI:229680
Molecular formula	C63H85N8O17+
Molecular weight	1226.4
InChIKey	LNFCWEXGZIEGJW-TXSVMFMRSA-O

SMILES: CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)OCC[N+](C)(C)C)O

IUPAC name: 2-[[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[[4-[4-(4-pentoxyphenyl)phenyl]benzoyl]amino]-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-21-yl]oxy]ethyl-trimethylazanium

ChEBI definition: A member of the family of echinocandins that inhibits 1,3-β-D-glucan synthase. It is developed by Cidara Therapeutics and approved for the treatment of candidaemia and invasive candidiasis in patients aged ≥ 18 years who have limited or no alternative treatment options.

Also known as: Biafungin, CD-101, CD101, Rezafungin, Rezafungin cation, Rezafungin ion, SP-3025, REZAFUNGIN

Parent form; salt/anhydrous children: CHEMBL3989928

Patent coverage: 536 distinct patent families (1,254 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
fungal infectious disease	1	MONDO:0002041	MONDO:0002041

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06774144	PHASE3	ENROLLING_BY_INVITATION	Rezafungin Prophylaxis in Liver Transplant
NCT03667690	PHASE3	COMPLETED	Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
NCT04368559	PHASE3	COMPLETED	Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
NCT05835479	PHASE2	RECRUITING	Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults
NCT02734862	PHASE2	COMPLETED	CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
NCT04117607	PHASE1	TERMINATED	Safety and Pharmacokinetics of Rezafungin
NCT06329518	PHASE1	WITHDRAWN	Rezafungin Pharmacokinetics in Patients on ECMO

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).